New successes in printing vascular tissue from living cells point to the accelerating pace of development of 3D-printing tissue — and eventually the ability to manufacture organs from small samples of cells.
Late last month Prellis Biologics announced an $8.7 million round of funding and some significant advancements that point the way forward for 3D-printed organs while a company called Volumetric Biobased on research from a slew of different universities unveiled significant progress of its own earlier this year.
The new successes from Prellis have the company speeding up its timeline to commercialization, including the sale of its vascular tissue structures to research institutions and looking ahead to providing vascularized skin grafts, insulin-producing cells and a vascular shunt made from the tissue of patients who need dialysis, according to an interview with Melanie Matheu, Prellis’ chief executive officer and co-founder.
The creation of a vascular shunt made from a patient’s own cells should increase the chances of the procedure working successfully, says Matheu. “[If] that shunt fails there aren’t many other options… and then people have ports put in their chest.” The proposed treatment from Prellis could increase quality of life and longevity of people who are waiting for a kidney,” according to Matheu.
The interplay between the skin microbiome and its host is a complex facet of dermatological…
A group of researchers from China have identified Insulin-like Growth Factor 2 (IGF2) in oral…
VitroScreen ORA® series are scaffold free spheroids acting as Micro Physiological Systems applicable to Pharmaceutical,…